BMS Grows Its Lung Cancer Portfolio With ‘Best-In-Class’ Augtyro Approval

Drug Addresses 1%-2% Of NSCLC Patients

Bristol Myers Squibb won US FDA approval for Augtyro (repotrectinib), from its $4.1bn Turning Point acquisition last year, in the treatment of ROS1-positive non-small cell lung cancer (NSCLC).

Lungs anatomy part glowing light X-ray abstract concept vector illustration
ROS1-positive NSCLC patients tend to be younger and women • Source: Shutterstock

Bristol Myers Squibb Company already is a dominant player in the non-small cell lung cancer (NSCLC) market with its PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab), but the big pharma continues to build up its presence in the space. The US Food and Drug Administration approved Bristol’s ROS1/NTKK inhibitor Augtyro (repotrectinib) on 15 November for adults with locally advanced or metastatic ROS1-positive NSCLC, including both treatment-naïve and treatment-experienced patients.

Key Takeaways
  • BMS won US FDA approval for Augtyro (repotrectinib) as a treatment for ROS1-positive NSCLC in first-line and treatment-experienced patients. 
  • The company believes it has a best-in-class drug, acquired in its $4.1bn Turning Point acquisition last year, that could generate $500m-$1bn in peak sales

BMS acquired Augtyro in the $4.1bn purchase of Turning Point Therapeutics Inc. last year, betting that repotrectinib’s best-in-class clinical trial results would help the company grow its revenue beyond the loss of exclusivity for Opdivo and other blockbuster products later in this decade

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

In Brief: US FDA Delay Sends Biohaven Shares Down

 

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By 

As CEO Anderson backs high prices for innovative drugs in Europe

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

More from Scrip

Regeneron Wins PCSK9 Court Battle Against Amgen

 

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By 

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 

Company surprises investors with Jørgensen's exit but insists its strategy will not change.